Numerous population studies confirm the high prevalence of hypertension in type II diabetic (DM2) subjects and that intensive antihypertensive treatment is more beneficial to diabetic than to nondiabetic hypertensive subjects, yet not many of these are specific to Spain. To assess the degree of blood pressure (BP) control and the effects of antihypertensive drugs in the medical management of hypertension in diabetic patients in specialist care centres throughout Spain, we studied the socio-demographic, clinical and relevant laboratory parameters of 796 hypertensive patients with DM2 (mean age 66.09 (95% confidence interval (CI): 64.08-68.10). The percentage of diabetic patients responding positively to BP control measures was lower when compared to the nondiabetic population in both Spain and Europe. The degree of control was poorer for systolic than for diastolic BP, yet 40.6% of the patients were only on monotherapy. The fact that antihypertensive treatment was modified in only 40% of the poorly controlled patients was also highly significant and could be attributed to a nonstringent use of clinical guidelines. Among the other differences between well-controlled and poorly controlled patients, we found that wellcontrolled patients presented with lower levels of cholesterol and triglycerides, a lower prevalence of excess weight/obesity, and a greater prevalence of cardiovascular and/or cerebrovascular disease despite having a greater percentage of patients on antiplatelet therapy. Better application of therapeutic guidelines and the prevention and treatment of compounding factors could improve the response rate to BP control measures in poorly controlled patients.
Introduction
High blood pressure (BP) is strongly associated with type II diabetes mellitus (DM2), 1 with many population studies confirming the high prevalence of hypertension in type II diabetic subjects. [2] [3] [4] [5] It is also known that in hypertensive subjects, renal and cardiovascular risk is much greater if the patient is diabetic than nondiabetic 3, 4, 6, 7 and that intensive antihypertensive treatment is more beneficial to diabetic than to nondiabetic hypertensive subjects. [8] [9] [10] In Spain, most of the studies that have assessed the degree of arterial BP control in patients with DM2 and hypertension have been conducted at a regional level.
11 Studies conducted at a national level have assessed the management of hypertension in primary care centres only. 12, 13 It is generally known that Spanish diabetic patients being treated in specialist care centres have a different profile to those being managed by primary care centres, mainly because they tend to be patients with a longer history of diabetes and with more microvascular and macrovascular complications. 11 Nonetheless, only one study has formally analysed the degree of BP control in a large group of patients with type II diabetes and hypertension managed within a specialist care centre environment in Spain. 14 The CLUE study 14 was undertaken to assess the degree of BP control and in particular the use, number and type of antihypertensive drugs used, and the medical management of a population of patients with DM2 and hypertension being followed up in specialist care centres.
With the Tarmidas study, however, we aimed to (a) evaluate the treatment and prevention strategies used in the management of diabetic hypertensive patients in specialist care centres in Spain; (b) evaluate the correlation between the degree of BP control achieved in these patients and the management plans used versus the recommendations made in the highly recognized and widely available good clinical practice/treatment guidelines; (c) assess the patient-and doctor-dependent factors behind the differences in the management of the same group of patients in different parts of Spain; and (d) study the relation between the existence of atherosclerosis and the degree of BP control.
Methods
The Tarmidas study This was an epidemiological, observational, prospective, crossover study on a cohort of the population of patients being treated in endocrinology and hypertension departments in Spain. Only patients diagnosed with both DM2 and raised BP were recruited onto the study. The study commenced on 15 June 2004 and patient recruitment ended on the 30 September 2004.
Subjects
Participants for this study were recruited from specialist care centres for type II diabetes and hypertension from all over Spain. The doctors, whose participation was voluntary, were instructed to include the first eight patients that attended outpatients clinic (as of the commencement date of the study) and were diagnosed previously with hypertension and DM2, independent of whether they were treated with insulin or not.
The inclusion criteria for entry into the study included:
(a) Diagnosis of hypertension -either previous diagnosis, established on antihypertensive drugs or with a recent diagnosis of hypertension as per the diagnostic criteria described in the 2003 ESH-ESC Guidelines 15 or JNC-7 criteria. 16 (b) Known diagnosis of type II diabetes mellitus (regardless of whether they were treated with oral hypoglycaemic agents or insulin) or if they fulfilled the diabetes criteria described in the 1998 WHO (World Health Organisation) Guidelines. 17 Patients could only be recruited if the disease appeared after the age of 30, and insulin was not required in the first 2 years following diagnosis.
(c) Availability of recent blood tests performed in the usual reference laboratories used by the participating doctors and obtained in the previous 2 months were considered to be valid for the purpose of this study. The required parameters included blood glucose, glycosylated haemoglobin, high-density lipoprotein, low-density lipoprotein and total cholesterol, triglycerides, uric acid, creatinine, sodium and potassium. The presence of microalbuminuria was also determined and, if present, quantified. The Medical Ethics Committee of the Hospital La Princesa in Madrid (Spain) approved the study. All the subjects gave informed written consent.
Clinical history and physical examination
The following information was collected for each subject: name; age; sex; time elapsed since diagnoses of DM and hypertension; chronic medication use (especially antidiabetic agents, antihypertensive agents, cholesterol-lowering drugs and antiaggregant agents); and a personal history of smoking, dyslipidaemia, sedentarism and vascular disease, cerebrovascular disease (CVD), ischaemic heart disease (IHD) or peripheral vascular disease (PVD). The drugs were classified into either antihypertensives (diuretics/b-blockers/a-blockers/dihydropyridines/ other calcium channel blockers/angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor antagonists) or other drugs.
A physical examination was conducted on each patient on the day of inclusion. The patient's weight, height and BP were measured and recorded. The most recent glycosylated haemoglobin (HbA 1c ), plasma creatinine, lipid profile and albuminuria results were also recorded.
Diagnostic criteria
Patients were considered to be hypertensive if they were taking antihypertensive medication, or if they fulfilled the diagnostic criteria described in the 2003 ESH-ESC Guidelines 15 or JNC-7 criteria. 16 The cutoff point of 130/80 mm Hg was used to determine whether a patient was controlled. Patients with a BP of 130/80 or more were therefore considered to be poorly controlled.
Patients were considered to have type II diabetes only if they fulfilled the diabetes criteria described in the 1998 WHO Guidelines, 17 the disease appeared after the age of 30, and insulin was not required in the first 2 years after diagnosis.
Patients were considered to have presented with any type of vascular disease only if a specialist had previously made the diagnosis and their diagnosis was recorded in the medical records.
A patient was considered to have microalbuminuria if the albuminuria excretion rate was between 30 and 300 mg/24 h or between 20 and 200 mg/min. On the other hand, a patient was considered to have proteinuria if the albuminuria excretion rate was equal to or exceeded 300 mg/24 h or 200 mg/min.
Patients were considered to be dyslipidaemic if they were taking cholesterol-lowering agents, had LDL-cholesterol levels greater than 100 mg/dl, or triglyceride levels over 150 mg/dl. 18 
Blood pressure measurements
In accordance with European Society of Hypertension and the European Society of Cardiology Hypertension Guidelines (ESH-ESC Guidelines) 15 and The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7) criteria, 16 systolic (SBP) and diastolic BP (DBP) levels were measured twice using the sphygmomanometer used by the physicians in their practice on a normal basis, with the mean of the two results used for the analysis. Pulse pressure was defined as SBP minus DBP. To analyse whether age had a bearing on the pulse pressure or not, the patients were grouped into four age groups: o50, 50-59, 60-69 and 70 or over.
Investigator information
For each study investigator, the following data was recorded: age, sex, place of employment and number of years as a specialist. Clinical management of hypertension by the specialist was classified in terms of one the following four categories: (a) no change in medication; (b) modification in medication and/or dosage; (c) combination with a new antihypertensive agent; and (d) substitution with another antihypertensive agent.
The data collected were from the last medical visit. Certain other data were collected from the penultimate visit. To this end, the patient's records were only available to the physicians for data recollection during the time of the medical visit (approximately half an hour).
Data collection, reduction and analysis
The study was conducted in accordance with the study protocol. The study data were recorded on a specially designed case report form and were carefully monitored by a Contract Research Organisation.
The decision to study 800 patients was predetermined on the basis of an estimate of a prevalence of BP control of 25%, a confidence interval (CI) of 95% and precision of 72%. Results were expressed in terms of frequency (%) for the qualitative variables, and as a mean7s.d. or 95% CIs. The Student's t-test was used to compare the means for independent samples and the w 2 test was used to assess possible associations between qualitative variables. The significance level was Po0.05. Binary logistic regression was used to determine which variables were linked to good BP control (BPo130/80 mm Hg). All statistical analyses were performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
Results
In total, 107 doctors from 16 Spanish Autonomous Communities participated in the study and data were collected from 796 patients ( Table 1) . Sixtyfour patients were excluded for failure to comply with selection criteria, or for having incoherent or incomplete data. There were no differences in the level of BP control between these groups. In total, only 637 (80%) of all the patients and 203 (72.25) of those on monotherapy were being treated with a renin-angiotensin-aldosterone (RAA) system blocker and only 59 (7.4%) were being treated with both an ACE inhibitor and an angiotensin II receptor antagonist. The percentage of patients being treated with a RAA system blocker was significantly greater (236 patients; 87.1%) in the albuminuria group than in the nonalbuminuria group (394 patients; 76.7%) (Po0.001).
Blood pressure
The significant differences between the controlled and uncontrolled BP groups were that the former presented with lower levels of total cholesterol, LDL-cholesterol and triglycerides (Table 2) , a lower prevalence of excess weight and obesity, a higher prevalence of a history of cardiovascular and CVD, and had a higher percentage of patients being treated with antiplatelet agents (Table 3) . Interestingly, it was also noted that the group with a longer history of diabetes also had more optimally controlled BP values (Table 2) . Furthermore, it was found that in the well-controlled group, the specialists had been in practice for 0.78 years or less. However, there were no significant differences in the age of the physician or their gender when it came to determining BP control (Table 4) .
Medication was modified in only 286 patients (35.9%) from the sample as a whole. Comparing the well-controlled group with the uncontrolled group, we found that the number of patients in whom the medication was modified was significantly lower in the former (four patients; 5.7%) than in the latter (282 patients; 38.8%) (Po0.001). Moreover, in the poorly controlled group, antihypertensive medication was increased in only 13 patients (4.6%), combined with another antihypertensive agent in 125 patients (17.2%) and changed in 144 patients (19.7%).
With the aim of identifying the factors associated with BP control, we performed a binary logistic regression analysis. The variables that predicted good control were as follows: CVD odds ratio 2.25 (95% CI: 1.07-4.75), IHD odds ratio 2.17 (95% CI: 1.30-4.14), body mass index of o28 odds ratio 1.91 (95% CI: 1.07-3.41) and LDL-cholesterol odds ratio 0.98 (95% CI: 0.97-0.98) ( Table 5 ). However, none of the investigator-dependent variables were found to be predictive of BP control. The goodness of fit was 91.6.
As an extension to the study, we also decided to study the prevalence of metabolic syndrome within the study population and its effect on BP control. 93.65% (CI 95% 91.6-95.1%) of the cohort had metabolic syndrome according to the ATP III criteria.
18 About 14.9% of patients without metabolic syndrome had shown good BP control versus 7.7% among those who appeared to have metabolic syndrome (Po0.095). 
Discussion
This study is one of the first Spanish studies to analyse the degree of BP control for a large population of patients with DM2 and hypertension managed in specialist care centres. The level of participation in all the regions of Spain was similar, thereby indicating that there was no bias in the sample.
Despite being treated with drugs, an increase in pulse pressure was observed in line with age, as described in other population studies. 19, 20 This highlights the difficulty of controlling the pulse pressure in diabetics, which is probably related to an increased stiffness of the arteries in diabetic patients due to early calcification, among other changes. 21 Large studies such as the Medical Research Council Mild Hypertension Trial and the Framingham Heart Study have indicated that pulse pressure is a better predictor of coronary heart disease than SBP or DBP. 22, 23 Furthermore, it has also been reported that high pulse pressure is associated with both microvascular and macrovascular complications in diabetic patients. 24 The control of BP in the Spanish hypertensive population was quite poor, with only 8.8% of the hypertensive subjects responding positively to treatment and other measures; a result that is similar to the recently published CLUE study where 10% of the patients treated at specialist care centres were controlled.
14 With respect to the patients treated at primary care centres, results show that 9.1 and 12.2% were controlled in the PRESCAP 12 and DIAPA 25 studies, respectively. In all these studies however, control was defined as achieving either a SBPp130 mm Hg and/or a DBP of p85 mm Hg. In an Italian study of 1782 type II diabetic patients receiving treatment in specialist and primary care centres, only 6% of the patients had BP control (defined as SBPp130 mm Hg and/or DBPp85 mm Hg). 26 In a French study of 3085 type II diabetic and hypertensive patients treated in specialist care centres, 23% of patients were found to be have good BP control. However, the BP definition of good control was also less stringent at SBPp140 mm Hg and/or DBPp80 mm Hg. 26 In comparison to these results from European countries, results obtained In Spain, the degree of BP control in nonepidemiological studies is clearly superior to that documented in population studies, regardless of whether the patient is treated in specialist or primary care centres. For example, in a study carried out in the Canary Islands town of Guía, only 4.8% of the sample studied presented with good BP control, with a significant proportion of patients (33.3%) having been neither diagnosed nor treated. This would strongly suggest that aside from improving the level of BP control in Spain, there is a serious need to both improve education and implement early detection programmes.
In our study, the percentage of diabetic patients responding positively to BP control measures is clearly lower than that for the nondiabetic population in Spain, [11] [12] [13] [14] as well as in Europe, [29] [30] [31] [32] where the percentage of controlled patients (defined as BPo140/90 mm Hg) ranges between 24 and 32%. This difference may be attributable to a greater difficulty in controlling BP in the diabetic population and to the fact that the less stringent BP targets for the nondiabetic hypertensive patients make it easier to achieve the target.
Furthermore, control was poorer for SBP than for DBP in our study as in virtually all other studies on BP control, [11] [12] [13] [14] and is closely related to the difficulty in achieving SBP targets. Furthermore, the relationship between systolic hypertension and cardiovascular mortality rates among diabetics is also well known. This is highly relevant as demonstrated in the Systolic Hypertension in the Elderly Program (SHEP) study 33 and the SYS-EUR study. 34 Likewise, a significant relationship has also been found between SBP and macrovascular and microvascular complications in the UKPDS study. 35 It is also noteworthy that despite poor BP control, a high proportion of patients (40.6%) were only receiving a single pharmacological agent. This was despite the proven need for multiple agents (at least two or three drugs) in numerous clinical studies. [35] [36] [37] [38] [39] [40] Within the group on monotherapy, as in the rest of the study population, it was difficult to say which antihypertensive agent or class of agents, if any, achieved better BP control as the study design did not enable us to draw these conclusions confidently.
More importantly, however, it was noted that antihypertensive treatment was only modified in 40% of the noncontrolled patients in our study -most likely to be attributable to the poor application of diagnostic and therapeutic guidelines. On the other hand, the percentage of patients taking three or more antihypertensive drugs (25.6%) was greater than that recorded for patients receiving treatment in primary care centres, 12 where only 8.4% of patients were found to be treated with three active compounds. This difference may be explained by the greater difficulty in controlling BP in the diabetic population, especially in the presence of arteriosclerosis.
In this study, it was also found that 80% of patients were also being treated with RAA system blockers. It has been proposed that subjects with hypertension and type II diabetes should be treated with renin angiotensin system blockers (either ACE inhibitors or angiotensin II receptor antagonists) due to preventive/protective benefits of these agents against the development and progression of nephropathy and cardiovascular disease. [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] The Blood Pressure Lowering Treatment Trialists' Collaboration meta-analysis of randomized trials, which included over 38 000 patients, found strong evidence of other benefits of ACE inhibitors for both diabetic and nondiabetic hypertensive patients. 40 The LIFE trial found that angiotensin II receptor antagonists markedly reduced total mortality and cardiovascular morbidity when compared to atenolol in 1195 diabetic hypertensive patients with left ventricular hypertrophy. 41 In the MICRO-HOPE study, treatment with an ACE inhibitor for 4-5 years was shown to reduce total and cardiovascular mortality in 3577 diabetes patients. 42 The BENE-DICT trial demonstrated that trandolapril, as a single agent or combined with verapamil decreases the incidence of microalbuminuria in hypertensive patients with type II diabetes, despite the fact that BP control to levels below 130/80 mm Hg was not optimized. 43 Yet another observational study has demonstrated that treatment with an ACE inhibitor over 3 years is associated with a reduction in total and cardiovascular mortality in patients without a previous history of cardiovascular disease. 44 However, there were no findings in the large UKPDS study 32 and in the ALLHAT study, 45 which indicated that treatment with RAAS blockers improved on treatment with diuretics and b-blockers in diabetic patients. Despite all the evidence available, however, it is noteworthy that only 72.2%% of patients on monotherapy, or 80% of all the patients in total, in our study were treated with a RAA system blocker.
The presence of excess weight and high LDL levels has also been identified as predictors of poor BP control in other trials. 46 In our trial, we found that the presence of metabolic syndrome meant that patients were half as likely as those without the syndrome to have good BP control. Nevertheless, as this study was neither powered nor designed to assess the relationship between metabolic syndrome and the control of hypertension, we cannot draw any definitive conclusions from this data.
Perhaps more controversial, however, was the finding that the presence of vascular disease is a predictor of good control. This is because the presence of vascular disease usually implies underlying structural damage, which in turn makes BP control more difficult. On the other hand, having suffered a vascular event also makes patients more conscientious about their drug compliance -an effect that has been demonstrated in a study that assessed the patient's attitude towards their own BP control. 47 Furthermore, physicians are usually more assertive when enforcing secondary preventative measures in the hypertensive diabetic patient and less so when enforcing primary preventative measures. This is despite recent evidence on the benefits of primary prevention, not only in terms of renal and heart protection but also cost/efficiency. 48 In conclusion, in our study we found that the degree of BP control, and especially SBP, was poor. In all, 35.3% of the patients were only on monotherapy and treatment was modified in only a mere 38.8% of the noncontrolled patients. Better application of therapeutic guidelines and the prevention or adequate and timely treatment of obesity may increase the percentage of patients responding well to arterial pressure control.
